

Vaccines and Related Biological Products Advisory Committee
(VRBPAC) Meeting – May 28, 2026

Voting Question for the Committee

1. For the 2026-2027 Formula of COVID-19 vaccines in the U.S., does the committee recommend JN.1-lineage XFG variant as the preferred variant for an updated monovalent vaccine?

Please vote “Yes” or “No” or “Abstain”

Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting – May 28, 2026



Discussion Topic for the Committee

- Please discuss circumstances that may warrant recommendation of a non-JN.1 lineage variant (e.g., BA.3.2) for COVID-19 vaccine use in the U.S.



U.S. FOOD & DRUG
ADMINISTRATION